Many Patients With Advanced Ovarian Cancer May Be Eligible For First-Line Maintenance With PARP Inhibitor

Cancer Therapy Advisor (7/8, Dembeck) reported, “Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, according to research.” Investigators “also found that patients treated with bevacizumab and those who have BRCA mutations are likely to have better outcomes.” The findings were published in Cancer.